{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T08:19:08Z","timestamp":1794903548103,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73131-y","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:17:38Z","timestamp":1779117458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0588-2060","authenticated-orcid":false,"given":"Junzhe","family":"Yi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiongliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6509-0372","authenticated-orcid":false,"given":"Yimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suixing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujia","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genjun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-3648","authenticated-orcid":false,"given":"Jibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8254-1040","authenticated-orcid":false,"given":"Ning","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"73131_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/1055-9965.EPI-24-0686","volume":"33","author":"KA McGlynn","year":"2024","unstructured":"McGlynn, K. A., Petrick, J. L. & Groopman, J. D. Liver cancer: progress and priorities. Cancer Epidemiol. Biomark. Prev. 33, 1261\u20131272 (2024).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"73131_CR2","unstructured":"Sun, J. et al. Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021)."},{"key":"73131_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/00000421-199808000-00014","volume":"21","author":"A Pawarode","year":"1998","unstructured":"Pawarode, A., Voravud, N., Sriuranpong, V., Kullavanijaya, P. & Patt, Y. Z. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am. J. Clin. Oncol. 21, 386\u2013391 (1998).","journal-title":"Am. J. Clin. Oncol."},{"key":"73131_CR4","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922\u20131965 (2023).","journal-title":"Hepatology"},{"key":"73131_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"73131_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862\u2013873 (2022).","journal-title":"J. Hepatol."},{"key":"73131_CR7","doi-asserted-by":"publisher","unstructured":"Breder, V. V. et al. IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and\/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. J. Clin. Oncol. 39, https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4073 (2021).","DOI":"10.1200\/JCO.2021.39.15_suppl.4073"},{"key":"73131_CR8","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1111\/liv.15458","volume":"42","author":"E Larrey","year":"2022","unstructured":"Larrey, E. et al. A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC. Liver Int. 42, 2843\u20132854 (2022).","journal-title":"Liver Int"},{"key":"73131_CR9","doi-asserted-by":"crossref","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 1, EVIDoa2100070, (2022).","DOI":"10.1056\/EVIDoa2100070"},{"key":"73131_CR10","doi-asserted-by":"publisher","first-page":"LBA4008","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","volume":"42","author":"PR Galle","year":"2024","unstructured":"Galle, P. R. et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. J. Clin. Oncol. 42, LBA4008\u2013LBA4008 (2024).","journal-title":"J. Clin. Oncol."},{"key":"73131_CR11","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 391, 1163\u20131173 (2018).","journal-title":"Lancet"},{"key":"73131_CR12","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet. Oncol. 24, 1399\u20131410 (2023).","journal-title":"Lancet. Oncol."},{"key":"73131_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000524893","volume":"11","author":"K Ueshima","year":"2022","unstructured":"Ueshima, K. et al. Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment. Liver cancer 11, 407\u2013425 (2022).","journal-title":"Liver cancer"},{"key":"73131_CR14","doi-asserted-by":"crossref","unstructured":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC). 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin. mol. Hepatol. 28, 583\u2013705, (2022).","DOI":"10.3350\/cmh.2022.0294"},{"key":"73131_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12072-023-10599-6","volume":"18","author":"M Zhao","year":"2024","unstructured":"Zhao, M. et al. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. Hepatol. Int. 18, 4\u201331 (2024).","journal-title":"Hepatol. Int."},{"key":"73131_CR16","doi-asserted-by":"publisher","unstructured":"Moris, D. et al. Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians. CA Cancer J. Clin., https:\/\/doi.org\/10.3322\/caac.70018 (2025).","DOI":"10.3322\/caac.70018"},{"key":"73131_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.21.01963","volume":"40","author":"N Lyu","year":"2022","unstructured":"Lyu, N. et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 40, 468\u2013480 (2022).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"73131_CR18","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He, M. et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 5, 953\u2013960 (2019).","journal-title":"JAMA Oncol."},{"key":"73131_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","volume":"31","author":"AS Mansfield","year":"2020","unstructured":"Mansfield, A. S. et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial. Ann. Oncol. 31, 310\u2013317 (2020).","journal-title":"Ann. Oncol."},{"key":"73131_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann. Oncol. 32, 983\u2013993 (2021).","journal-title":"Ann. Oncol."},{"key":"73131_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 398, 27\u201340 (2021).","journal-title":"Lancet."},{"key":"73131_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G. & Marincola, F. M. Targeting immunogenic cell stress and death for cancer therapy. Nat. Rev. Drug Discov. 23, 445\u2013460 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73131_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10142-024-01399-8","volume":"24","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Jiang, Q., Xue, Y., Chen, W. & Hua, M. CRISPR-Cas9-mediated deletion enhancer of MECOM play a tumor suppressor role in ovarian cancer. Funct. Integr. Genomics 24, 125 (2024).","journal-title":"Funct. Integr. Genomics"},{"key":"73131_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2147\/OTT.S97367","volume":"9","author":"GY Li","year":"2016","unstructured":"Li, G. Y., Huang, M., Pan, T. T. & Jia, W. D. Expression and prognostic significance of contactin 1 in human hepatocellular carcinoma. Onco. Targets Ther. 9, 387\u2013394 (2016).","journal-title":"Onco. Targets Ther."},{"key":"73131_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.canlet.2006.10.012","volume":"250","author":"WK Ip","year":"2007","unstructured":"Ip, W. K. et al. Identification of PEG10 as a progression-related biomarker for hepatocellular carcinoma. Cancer Lett. 250, 284\u2013291 (2007).","journal-title":"Cancer Lett."},{"key":"73131_CR26","doi-asserted-by":"publisher","first-page":"D900","DOI":"10.1093\/nar\/gky939","volume":"47","author":"H Yuan","year":"2019","unstructured":"Yuan, H. et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 47, D900\u2013d908 (2019).","journal-title":"Nucleic Acids Res."},{"key":"73131_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-020-00904-3","volume":"13","author":"H Hua","year":"2020","unstructured":"Hua, H., Kong, Q., Yin, J., Zhang, J. & Jiang, Y. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. J. Hematol. Oncol. 13, 64 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"73131_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13046-022-02475-2","volume":"41","author":"T Zhang","year":"2022","unstructured":"Zhang, T. et al. HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET. J. Exp. Clin. Cancer Res. 41, 275 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"73131_CR29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/hep.23747","volume":"52","author":"XF Zhang","year":"2010","unstructured":"Zhang, X. F. et al. Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha\/phosphoinositide 3-kinase signaling. Hepatology 52, 954\u2013965 (2010).","journal-title":"Hepatology"},{"key":"73131_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","volume":"29","author":"H Tang","year":"2016","unstructured":"Tang, H. et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29, 285\u2013296 (2016).","journal-title":"Cancer Cell"},{"key":"73131_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","volume":"18","author":"Q Hu","year":"2025","unstructured":"Hu, Q., Zhu, Y., Mei, J., Liu, Y. & Zhou, G. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J. Hematol. Oncol. 18, 65 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"73131_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102322","volume":"6","author":"KA Khan","year":"2025","unstructured":"Khan, K. A. et al. Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade. Cell Rep. Med. 6, 102322 (2025).","journal-title":"Cell Rep. Med."},{"key":"73131_CR33","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1158\/0008-5472.CAN-13-0218","volume":"73","author":"C Pola","year":"2013","unstructured":"Pola, C., Formenti, S. C. & Schneider, R. J. Vitronectin-\u03b1v\u03b23 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells. Cancer Res. 73, 4571\u20134578 (2013).","journal-title":"Cancer Res."},{"key":"73131_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12253-016-0138-6","volume":"23","author":"CC Nobre","year":"2017","unstructured":"Nobre, C. C. et al. Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer. Pathol. Oncol. Res. 23, 235\u2013244 (2017).","journal-title":"Pathol. Oncol. Res."},{"key":"73131_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S. & Llovet, J. M. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review. JAMA Oncol. 10, 395\u2013404 (2024).","journal-title":"JAMA Oncol."},{"key":"73131_CR36","doi-asserted-by":"publisher","unstructured":"Chiang, C. L. et al. Complete response to locoregional therapy plus immunotherapy for hepatocellular carcinoma. JAMA Oncol, https:\/\/doi.org\/10.1001\/jamaoncol.2024.4085 (2024).","DOI":"10.1001\/jamaoncol.2024.4085"},{"key":"73131_CR37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","volume":"6","author":"D Tai","year":"2021","unstructured":"Tai, D. et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet. Gastroenterol. Hepatol. 6, 1025\u20131035 (2021).","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"73131_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 293\u2013313 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"73131_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang, C. L. et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 169\u2013178 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"73131_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.livres.2024.09.002","volume":"8","author":"W Abdelhamed","year":"2024","unstructured":"Abdelhamed, W., Shousha, H. & El-Kassas, M. Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end? Liver Res.8, 141\u2013151 (2024).","journal-title":"Liver Res."},{"key":"73131_CR41","first-page":"655","volume":"13","author":"RS Finn","year":"2024","unstructured":"Finn, R. S. et al. Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in imbrave150. Liver Cancer 13, 655\u2013668 (2024).","journal-title":"Liver Cancer"},{"key":"73131_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Buqu\u00e9, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97\u2013111 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"73131_CR43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buqu\u00e9, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"73131_CR44","doi-asserted-by":"publisher","first-page":"334ra352","DOI":"10.1126\/scitranslmed.aad8307","volume":"8","author":"MJ Welters","year":"2016","unstructured":"Welters, M. J. et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci. Transl. Med. 8, 334ra352 (2016).","journal-title":"Sci. Transl. Med."},{"key":"73131_CR45","doi-asserted-by":"publisher","unstructured":"Melief, C. J. M. et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Sci. Transl. Med. 12, https:\/\/doi.org\/10.1126\/scitranslmed.aaz8235 (2020).","DOI":"10.1126\/scitranslmed.aaz8235"},{"key":"73131_CR46","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro, B., Sarobe, P., Hervas-Stubbs, S. & Melero, I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 525\u2013543 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"73131_CR47","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599\u20131611 (2022).","journal-title":"Nat. Med."},{"key":"73131_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01877-w","volume":"22","author":"Z Zeng","year":"2023","unstructured":"Zeng, Z. et al. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. Mol. Cancer 22, 172 (2023).","journal-title":"Mol. Cancer"},{"key":"73131_CR49","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","volume":"19","author":"SJ Hogg","year":"2020","unstructured":"Hogg, S. J., Beavis, P. A., Dawson, M. A. & Johnstone, R. W. Targeting the epigenetic regulation of antitumour immunity. Nat. Rev. Drug Discov. 19, 776\u2013800 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73131_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.81","volume":"48","author":"SM Jeon","year":"2016","unstructured":"Jeon, S. M. Regulation and function of AMPK in physiology and diseases. Exp. Mol. Med. 48, e245 (2016).","journal-title":"Exp. Mol. Med."},{"key":"73131_CR51","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","volume":"30","author":"HD Kim","year":"2024","unstructured":"Kim, H. D. et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat. Med. 30, 699\u2013707 (2024).","journal-title":"Nat. Med."},{"key":"73131_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00995-8","volume":"14","author":"JY Hong","year":"2022","unstructured":"Hong, J. Y. et al. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med. 14, 1 (2022).","journal-title":"Genome Med"},{"key":"73131_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3395-1","volume":"17","author":"M Shibutani","year":"2017","unstructured":"Shibutani, M. et al. The peripheral monocyte count is associated with the density of tumor-associated macrophages in the tumor microenvironment of colorectal cancer: a retrospective study. BMC Cancer 17, 404 (2017).","journal-title":"BMC Cancer"},{"key":"73131_CR54","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1158\/0008-5472.CAN-17-3876","volume":"78","author":"V Quaranta","year":"2018","unstructured":"Quaranta, V. et al. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Cancer Res. 78, 4253\u20134269 (2018).","journal-title":"Cancer Res."},{"key":"73131_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369\u2013382 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"73131_CR56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.lungcan.2018.08.012","volume":"124","author":"K Sekine","year":"2018","unstructured":"Sekine, K. et al. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer 124, 179\u2013188 (2018).","journal-title":"Lung Cancer"},{"key":"73131_CR57","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/jjco\/hyg077","volume":"33","author":"S Sadahiro","year":"2003","unstructured":"Sadahiro, S. et al. Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model. Jpn. J. Clin. Oncol. 33, 377\u2013381 (2003).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"73131_CR58","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/COC.0b013e31819d8668","volume":"33","author":"R Rathore","year":"2010","unstructured":"Rathore, R. et al. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. Am. J. Clin. Oncol. 33, 43\u201346 (2010).","journal-title":"Am. J. Clin. Oncol."},{"key":"73131_CR59","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/1078-0432.CCR-18-0847","volume":"25","author":"L Goyal","year":"2019","unstructured":"Goyal, L. et al. A phase ii and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 25, 80\u201389 (2019).","journal-title":"Clin. Cancer Res"},{"key":"73131_CR60","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","volume":"31","author":"S Qin","year":"2013","unstructured":"Qin, S. et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 31, 3501\u20133508 (2013).","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"73131_CR61","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/gutjnl-2017-314138","volume":"67","author":"N Lyu","year":"2018","unstructured":"Lyu, N. et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin for advanced hepatocellular carcinoma. Gut. 67, 395\u2013396 (2018).","journal-title":"Gut"},{"key":"73131_CR62","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","volume":"69","author":"N Lyu","year":"2018","unstructured":"Lyu, N. et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J. Hepatol. 69, 60\u201369 (2018).","journal-title":"J. Hepatol."},{"key":"73131_CR63","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1055\/a-1939-4887","volume":"54","author":"IM Gralnek","year":"2022","unstructured":"Gralnek, I. M. et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 54, 1094\u20131120 (2022).","journal-title":"Endoscopy"},{"key":"73131_CR64","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cgh.2021.01.027","volume":"19","author":"Z Henry","year":"2021","unstructured":"Henry, Z., Patel, K., Patton, H. & Saad, W. AGA clinical practice update on management of bleeding gastric varices: expert review. Clin. Gastroenterol. Hepatol. 19, 1098\u20131107.e1091 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"73131_CR65","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41587-020-00795-2","volume":"39","author":"R Gao","year":"2021","unstructured":"Gao, R. et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat. Biotechnol. 39, 599\u2013608 (2021).","journal-title":"Nat. Biotechnol."},{"key":"73131_CR66","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","volume":"184","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 184, 404\u2013421.e416 (2021).","journal-title":"Cell"},{"key":"73131_CR67","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nmeth.4402","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu, X. et al. Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods 14, 979\u2013982 (2017).","journal-title":"Nat. Methods"},{"key":"73131_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"73131_CR69","doi-asserted-by":"publisher","first-page":"CT009","DOI":"10.1158\/1538-7445.AM2021-CT009","volume":"81","author":"RS Finn","year":"2021","unstructured":"Finn, R. S. et al. Abstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC). Cancer Res. 81, CT009\u2013CT009 (2021).","journal-title":"Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73131-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73131-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73131-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:46:19Z","timestamp":1794901579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73131-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73131"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73131-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of Supplementary Information initially published alongside this article, Supplementary Fig. 6 was an inadvertent duplicate of Supplementary Fig. 5. The Supplementary Information are updated in the HTML version of the article.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7837"}}